Radius Health Inc. is a Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology.
Radius Health Inc. (RDUS) had a good day on the market for Friday December 04 as shares jumped 1.4% to close at $14.80. About 226,035 shares traded hands on 2,443 trades for the day, compared with an average daily volume of n/a shares out of a total float of 46.55 million. After opening the trading day at $14.55, shares of Radius Health Inc. stayed within a range of $14.86 to $14.42.
With today’s gains, Radius Health Inc. now has a market cap of $688.9 million. Shares of Radius Health Inc. have been trading within a range of $23.22 and $10.16 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company’s product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140.
Radius Health Inc. is based out of Waltham, MA and has some 383 employees. Its CEO is G. Kelly Martin.